Immunoproliferative Disorders D007160

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders

Description

Disorders characterized by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins.   MeSH

Subtype Terms (3)

Lymphoproliferative Disorders
122 drugs (83 approved, 39 experimental)

Paraproteinemias
27 drugs (23 approved, 4 experimental)


Phase 3 Indicated Drugs (2)

Other Experimental Indicated Drugs (1)


Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.